HD-OPM Archive
Topics › PCSK9, ezetimibe & newer drugs

PCSK9 inhibitor plus statin nearly halted coronary calcium progression versus statin alone

Gokhan Can · Dec 01, 2025 · ♥ 14 reactions · 4 comments · original Facebook post
PCSK9, ezetimibe & newer drugsPlaque, CAC & CT angiographyLp(a)
AI summary & key facts

Summary of alirocumab 75 mg biweekly added to moderate statins in 61 CAD patients over 18 months: median CAC +2.9% vs +10.6%, with CAC not rising significantly from baseline. A retrospective study (Ikegami, n=120) found about half the annual calcium progression. Mechanism is thought to be stronger LDL and Lp(a) lowering.

PCSK9 Inhibitors and Coronary Artery Calcium (CAC) Progression

Overview

PCSK9 inhibitors, such as alirocumab and evolocumab, are potent injectable agents that dramatically lower LDL cholesterol and reduce Lipoprotein(a) [Lp(a)]. While statins alone have minimal impact on slowing the accumulation of coronary calcium, emerging evidence indicates that adding a PCSK9 inhibitor can significantly attenuate CAC progression and stabilize plaque in high-risk patients [1][2].

Clinical Evidence

Recent studies distinguish the effects of PCSK9 inhibition from standard statin monotherapy:

Mechanism of Action

The ability of PCSK9 inhibitors to slow calcification is thought to stem from aggressive lipid modulation. In clinical trials, alirocumab reduced LDL levels to ~30–50 mg/dL and significantly lowered Lp(a), a risk factor statins typically do not affect. Analyses suggest that the reduction in Lp(a) correlates directly with the slowed progression of CAC, implying that Lp(a) lowering may be a key mediator of this benefit [1].

Clinical Implications

While larger long-term studies are needed, current data supports the use of PCSK9 inhibitors for secondary prevention or very high-risk primary prevention (e.g., familial hypercholesterolemia or high CAC scores). In these populations, adding a PCSK9 inhibitor to maximally tolerated statins appears to not only regress soft plaque but also prevent the rapid progression of calcified plaque often seen with statin monotherapy [2].
References

Paper · Front. Cardiovasc. Med. · 2022Effect of Alirocumab on Coronary Calcification in Patients With Coronary Artery DiseaseBackground Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been documented with significantly reduction in LDL cholesterol levels and cardiovascular events. However, evidence regarding the impact of PCSK9 inhibitors on coronary calcification is limited. Methods Eligible patients with intermediate coronary lesions and elevated LDL cholesterol values were randomized to either alirocumab 75 mg Q2W…frontiersin.org

[2] The annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapy (Ikegami et al., 2018)

PaperThe annual rate of coronary artery calcification with combination therapy with a PCSK9 inhibitor and a statin is lower than that with statin monotherapyresearchgate.net

[3] Coronary Artery Calcium Progression: An Update (Frontiers in Cardiovascular Medicine, 2020)

Paper · Front. Cardiovasc. Med. · 2020Coronary Artery Calcification Under Statin Therapy and Its Effect on Cardiovascular Outcomes: A Systematic Review and Meta-AnalysisObjective: To compare Agatston scores between patients without statin therapy and those under standard and intensive statin therapy and to systematically review the relationship between coronary artery calcification (CAC) progression under statin therapy and cardiovascular outcomes. Methods: Literature search was conducted across databases. Randomized controlled trials and observational studies that reported…frontiersin.org Paper · Atherosclerosis · 2022PCSK9 promotes arterial medial calcificationsciencedirect.com

Research cited

#statins#pcsk9#cardiovascular#calcification#calcium#plaque#prevention#riskfactors
← newer: Admin's bibimbap without rice as a Mediterranean-style Koreaolder: CARDIA: low-carb diets in young adults tied to more coronary →